6 recruiting, 5 completed, 3 unknown, 2 active not recruiting. 15 Phase 1, 4 Phase 2, 2 Phase 3.
Follow Metastatic Tumor: new trials by email Literature Review of Metastatic Tumor trials Research Report on Metastatic Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors 5 Azacytidine, Pembrolizumab, Nivolumab - Solid Tumor, Locally Advanced Solid Tumor | Phase 1 | Recruiting | Mohammed Milhem | 35 | 2026-02-11 | 2026-05-28 |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NKT3964, Paclitaxel, Doxorubicin - Solid Tumor, Advanced Solid Tumor | Phase 1 | Recruiting | NiKang Therapeutics, Inc. | 238 | 2024-09-19 | 2026-11-05 |
| A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors CHT101 - Metastatic Tumor, Advanced Solid Tumor | Phase 1 | Not yet recruiting | Zhejiang University | 18 | 2024-04-22 | 2024-04-25 |
| A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NKT3447 - Solid Tumor, Solid Tumor, Adult | Phase 1 | Terminated | NiKang Therapeutics, Inc. | 23 | 2024-02-23 | 2025-09-25 |
| Definitive Radiation for High-Risk Spine Metastases SBRT to the spine - Metastatic Cancer, Metastatic Lung Cancer | Phase 2 | Recruiting | Stony Brook University | 26 | 2023-12-14 | 2025-05-14 |
| A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor. Palliative Radiotherapy, Chemotherapy, Hormone therapy - Metastatic Tumor | Phase 3 | Recruiting | David Palma | 180 | 2023-10-06 | 2025-12-31 |
| A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer AZD1390, Stereotactic Body Radiotherapy - Solid Tumor, Metastatic Solid Tumor | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 54 | 2023-05-17 | 2026-05-18 |
| Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy Ipilimumab Injection, Atezolizumab Injection, Bevacizumab - HCC - Hepatocellular Carcinoma, Metastatic Cancer | Phase 2 / Phase 3 | Completed | Federation Francophone de Cancerologie Digestive | 229 | 2023-03-09 | 2026-03-09 |
| A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors TST003 - Locally Advanced Solid Tumor, Metastatic Tumor | Phase 1 / Phase 2 | Active not recruiting | Transcenta Therapeutics (Hangzhou) Co., Ltd. | 111 | 2023-02-08 | 2026-09-29 |
| A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T CD70 CAR-T cells - Metastatic Tumor, Advanced Solid Tumor | Phase 1 | Unknown | Chongqing Precision Biotech Co., Ltd | 48 | 2022-07-17 | 2023-08-18 |
| A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors CD70 CAR-T cells - Metastatic Tumor, Advanced Solid Tumor | Phase 1 | Recruiting | Weijia Fang, MD | 30 | 2022-05-30 | 2025-05-31 |
| Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer CD70 CAR-T cells - Metastatic Tumor, Renal Cell Carcinoma | Phase 1 | Unknown | Chongqing Precision Biotech Co., Ltd | 24 | 2021-12-31 | 2023-08-18 |
| A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors CD70 CAR-T cells - Metastatic Tumor, Advanced Solid Tumor | Phase 1 | Unknown | Chongqing Precision Biotech Co., Ltd | 36 | 2021-12-31 | 2023-08-18 |
| Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers AFM24, SNK01 - Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Terminated | NKGen Biotech, Inc. | 11 | 2021-11-03 | 2024-03-01 |
| Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors CEA CAR-T cells - Colorectal Cancer, Esophageal Cancer | Phase 1 | Completed | Chongqing Precision Biotech Co., Ltd | 30 | 2021-09-10 | 2026-07-09 |
| A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors Axatilimab, Durvalumab - Solid Tumor, Metastatic Tumor | Phase 1 | Completed | Syndax Pharmaceuticals | 45 | 2017-09-01 | 2024-05-17 |
| Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. Pexa-Vec, Ipilimumab - Metastatic Tumor, Advanced Tumor | Phase 1 | Completed | Centre Leon Berard | 22 | 2017-01-03 | 2022-07-25 |
| Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients Docetaxel, Apalutamide Oral Tablet, Enzalutamide Oral Tablet - Prostate Cancer, Hormone Sensitive Prostate Cancer | Recruiting | Santa Chiara Hospital | 3000 | 2016-12-16 | 2024-06-25 | |
| A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread LY2334737 - Malignant Solid Tumor, Solid Tumor | Phase 1 | Completed | Eli Lilly and Company | 73 | 2008-09-01 | 2019-06-17 |
Neoplasm Metastasis (19) · Ovarian Neoplasms (6) · Carcinoma, Renal Cell (5) · Uterine Cervical Neoplasms (4) · Stomach Neoplasms (3) · Colorectal Neoplasms (2) · Endometrial Neoplasms (2) · Lung Neoplasms (2) · Small Cell Lung Carcinoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Triple Negative Breast Neoplasms (2) · Uterine Diseases (2) · Bone Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1)
Neoplastic Processes (19) · Pathologic Processes (19) · Pathological Conditions, Signs and Symptoms (19) · Neoplasms (18) · Neoplasms by Site (12) · Urogenital Diseases (8) · Urogenital Neoplasms (8) · Carcinoma (7) · Endocrine Gland Neoplasms (7) · Endocrine System Diseases (7) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Genital Diseases (7) · Neoplasms by Histologic Type (7) · Neoplasms, Glandular and Epithelial (7)
Ipilimumab (2) · AZD1390 (1) · Abiraterone Acetate (1) · Azacitidine (1) · Bevacizumab (1) · Docetaxel (1) · Doxorubicin (1) · Drug Therapy (1) · Immunotherapy (1) · LY2334737 (1) · Nivolumab (1) · Observation (1) · Paclitaxel (1) · Radiofrequency Therapy (1) · Radiosurgery (1)
Chongqing Precision Biotech Co., Ltd (4) · NiKang Therapeutics, Inc. (2) · Centre Leon Berard (1) · David Palma (1) · Eli Lilly and Company (1) · Federation Francophone de Cancerologie Digestive (1) · Memorial Sloan Kettering Cancer Center (1) · Mohammed Milhem (1) · NKGen Biotech, Inc. (1) · Santa Chiara Hospital (1) · Stony Brook University (1) · Syndax Pharmaceuticals (1) · Transcenta Therapeutics (Hangzhou) Co., Ltd. (1) · Weijia Fang, MD (1) · Zhejiang University (1)
United States (9) · China (5) · France (3) · Canada (1) · Germany (1) · Italy (1) · South Korea (1) · Switzerland (1)
Jianfeng Bi, M.D (2) · Daniel Higginson, MD (1) · Jingwang Bi, M.D (1) · Kartik Mani, MD PhD (1) · Kate Madigan, MD (1) · Mohammed Milhem, MD (1) · Paul Chang, MPH (1) · Quanli Gao, M.D (1) · Weijia Fang, M.D (1)
PMID 39244532, PMID 39704205, PMID 42330996
2008 (1)